KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Kymera Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$108.07+3.29 (+3.14%)
Close on Oct 19, 2026
- Market cap
- $10.61B
- P/E (TTM)
- –
- Dividend yield
- –
Kymera Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 0.0%
- Operating margin
- -333.5%
- Net margin
- -285.3%
- Return on equity, FY2025
- -25.8%
Financial strength
- Current ratio
- 10.34
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 174.5%
Valuation
- P/E ratio
- –
- Price to sales
- 101.05
- Price to book
- 7.03
- Dividend yield
- –